You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)與江蘇康寧傑瑞就KN026開發及商業化簽訂獨家授權協議

格隆匯8月23日丨石藥集團(01093.HK)發佈公吿,公司全資附屬公司津曼特生物已與康寧傑瑞製藥-B(09966.HK)附屬公司江蘇康寧傑瑞於2021年8月23日訂立協議,內容有關江蘇康寧傑瑞在研產品KN026(一種靶向HER2的雙特異性抗體)在乳腺癌及胃癌的獨家開發及商業化授權。

根據該協議的條款,津曼特生物將獲得該產品的獨家權利,以於中國大陸進行該產品單藥以及與KN046聯合在乳腺癌、胃癌的開發與商業化,承擔有關的臨牀開發費用併成為上市許可持有人(MAH);及2與江蘇康寧傑瑞共同開發KN026其它適應症,包括KN026單藥及組合用藥。

作為該授權的代價,津曼特生物同意向江蘇康寧傑瑞支付人民幣1.5億元的首付款及根據該產品於該地區的開發進度支付最多人民幣4.5億元的開發里程碑付款。津曼特生物亦同意根據該產品就該領域於該地區達成的淨銷售額向江蘇康寧傑瑞支付最多人民幣4億元的潛在銷售里程碑付款和兩位數百分比的分層銷售提成。

根據披露,KN026是江蘇康寧傑瑞研發的具有自主知識產權的靶向HER2的雙特異性抗體藥物,目前KN026正在中美同步展開多項I/II期臨牀研究,用於評估治療HER2中低表達或HER2陽性乳腺癌、晚期HER2陽性胃癌和胃食管結合部癌及其它HER2陽性實體瘤等適應症的潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account